Intravenous heparin did not prevent exacerbations of hereditary angioedema in a patient on maintenance hemodialysis

To the Editor In a recent article concerning the safety and efficacy of inhaled and subcutaneous heparin versus that of placebo in the prevention of hereditary angioedema (HAE) attacks (in the June 2002 issue of The Journal of Allergy and Clinical Immunology ), Weiler et al1 demonstrated that commer...

Full description

Saved in:
Bibliographic Details
Published in:Journal of allergy and clinical immunology 2003-05, Vol.111 (5), p.1137-1137
Main Authors: Perricone, Roberto, De Carolis, Caterina, Fontana, Luigi
Format: Article
Language:English
Subjects:
Angioedema
Angioedema - prevention & control
Hemodialysis
Heparin - administration & dosage
Heparin - therapeutic use
Hepatitis
Humans
Injections, Intravenous
Medical research
Renal Dialysis - adverse effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To the Editor In a recent article concerning the safety and efficacy of inhaled and subcutaneous heparin versus that of placebo in the prevention of hereditary angioedema (HAE) attacks (in the June 2002 issue of The Journal of Allergy and Clinical Immunology ), Weiler et al1 demonstrated that commercial heparin (either subcutaneously injected or inhaled) was ineffective in preventing exacerbations of HAE.
ISSN:0091-6749
1097-6825
DOI:10.1067/mai.2003.1461